Transmedics Group Inc

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Earnings data Q2 2026

TransMedics reports record Q2 revenue, eyes transplant logistics expansion

TransMedics Group Inc's Q2 earnings call highlighted robust performance, strategic acquisitions, and ambitious growth targets, underpinning their market position.
While facing challenges in profitability and operational timelines, the company's focus on enhancing logistics and expanding revenue streams signals a promising trajectory.
Investors should monitor TransMedics' execution of growth plans, including the aviation fleet expansion and next-gen lung system integration, for future value creation.

TransMedics reports stellar Q3 results, eyes expansion and efficiency

TransMedics Group Inc's Q3 earnings call highlighted exceptional revenue growth, operational achievements, and strategic acquisitions, positioning the company for continued success.
The company's focus on revenue diversification, operational efficiency, and innovation underscores its commitment to driving growth and improving patient outcomes.
Despite challenges in growth analysis and program limitations, TransMedics remains optimistic about future opportunities and is poised to capitalize on market trends.

Transmedics Group reports robust earnings, eyes growth in transplant services

Transmedics Group Inc (TMDX) delivered strong financial results in Q4 and full-year 2023, showcasing revenue growth and operational profitability, despite margin pressures.
The company's focus on expanding transplant logistics services, addressing concerns, and presenting data analysis at conferences highlights its commitment to growth and innovation.
With strategic initiatives planned for 2024, TransMedics aims to drive market share in heart, liver, and lung transplants, capitalize on growth opportunities, and enhance operational efficiency for sustained success.
Confidence in providing cost-effective transplant logistics and plans for equal contribution from all three organs position TransMedics for future growth and market leadership in the transplant industry.

TransMedics reports robust Q1 earnings, eyes global expansion and innovation

TransMedics Group Inc (TMDX) delivered strong Q1 2024 results, with notable revenue growth and margin improvement, setting the stage for continued expansion and innovation in the transplant industry.
The company's strategic focus on next-gen technology platforms, new clinical programs, and international market expansion positions it well for sustained growth and leadership in the sector.
While facing challenges in margin improvement and market acceptance, TransMedics has the opportunity to leverage its strengths in product innovation and global appeal to drive future success.

Transmedics Group Inc (TMDX) excels in Q2, eyes clinical program growth

Transmedics Group Inc delivered a stellar performance in Q2 2024, marked by robust revenue growth, operational profitability, and positive free cash flow.
The company's strategic initiatives to expand the aviation fleet, launch new clinical programs, and raise revenue guidance demonstrate a focus on innovation and growth.
While facing challenges in program launches and market competition, Transmedics remains well-equipped to leverage opportunities for market expansion and sustained success.

Transmedics reports robust Q3 performance amidst market challenges

Transmedics Group Inc delivered strong financial results in Q3 2024, driven by robust U.S. sales growth and strategic investments in infrastructure and technology.
While facing challenges with declining transplant volumes and margin pressures, the company remains focused on long-term growth initiatives and maintaining operational efficiency.
Opportunities lie in optimizing international sales, exploring new growth avenues, and leveraging innovative technologies to drive future revenue and market expansion.

Transmedics reports stellar Q4 results, eyes growth through innovation

Transmedics Group Inc (TMDX) delivered impressive financial results in Q4 2024 and outlined a positive outlook for 2025, focusing on strategic growth initiatives. Despite operational challenges ahead, the company remains confident in its ability to navigate complexities and achieve its revenue targets through proactive measures. Investors can look forward to continued revenue growth, market expansion, and innovation as Transmedics positions itself for sustained success in the medical technology sector.

TransMedics reports stellar Q1 results, raises 2025 revenue guidance

TransMedics Group Inc delivered a strong performance in Q1 2025, with robust revenue growth, improved profitability, and strategic initiatives to drive innovation and market expansion. While facing potential challenges in maintaining momentum and navigating market variability, the company remains confident in its ability to sustain growth and capitalize on opportunities in the healthcare sector. With a focus on efficiency, sustainability, and financial strength, TransMedics is well-positioned to leverage its strengths, address challenges, and seize opportunities for continued success and market leadership.

Transmedics reports robust Q2 earnings, eyes international expansion for growth

Transmedics Group Inc (TMDX) delivered strong financial results in Q2 2025, showcasing revenue growth, profitability, and cash generation, positioning the company for future success. Despite potential challenges such as seasonality and international expansion complexities, Transmedics' strategic initiatives and product pipeline advancements offer growth opportunities and market leadership potential. Investors should monitor Transmedics' execution of its expansion plans, clinical program launches, and revenue guidance targets to assess the company's ability to capitalize on market opportunities and drive sustainable growth.

TransMedics reports robust Q4 earnings, eyes European expansion in 2026

TransMedics Group Inc (TMDX) delivered strong financial results in Q4 and full year 2025, driven by revenue growth and operational efficiency. The company's strategic focus on expanding OCS programs and entering new markets positions it well for continued growth. While challenges exist in maintaining efficiency and navigating new markets, TransMedics has significant opportunities for revenue growth and margin expansion in 2026 and beyond.

Transmedics Group Inc reports robust Q1 performance and eyes market expansion

Transmedics Group Inc's Q1 2026 performance reflects strong revenue growth, operational efficiency, and financial stability, positioning the company for future success. Strategic investments in innovative products and market expansion efforts demonstrate a commitment to driving growth and maintaining competitive advantage. While facing challenges in donor numbers and cost management, Transmedics is poised to capitalize on opportunities in product development, market expansion, and regulatory approvals.